Remote and Long-Term Self-Monitoring of Electroencephalographic and Noninvasive Measurable Variables at Home in Patients With Epilepsy (EEG@HOME): Protocol for an Observational Study.
EEG
brain
brain ictogenicity
electroencephalography
epilepsy
mobile technology
seizure prediction
seizures
wearables
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
19 Mar 2021
19 Mar 2021
Historique:
received:
27
10
2020
accepted:
23
12
2020
revised:
22
12
2020
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
20
3
2021
Statut:
epublish
Résumé
Epileptic seizures are spontaneous events that severely affect the lives of patients due to their recurrence and unpredictability. The integration of new wearable and mobile technologies to collect electroencephalographic (EEG) and extracerebral signals in a portable system might be the solution to prospectively identify times of seizure occurrence or propensity. The performances of several seizure detection devices have been assessed by validated studies, and patient perspectives on wearables have been explored to better match their needs. Despite this, there is a major gap in the literature on long-term, real-life acceptability and performance of mobile technology essential to managing chronic disorders such as epilepsy. EEG@HOME is an observational, nonrandomized, noninterventional study that aims to develop a new feasible procedure that allows people with epilepsy to independently, continuously, and safely acquire noninvasive variables at home. The data collected will be analyzed to develop a general model to predict periods of increased seizure risk. A total of 12 adults with a diagnosis of pharmaco-resistant epilepsy and at least 20 seizures per year will be recruited at King's College Hospital, London. Participants will be asked to self-apply an easy and portable EEG recording system (ANT Neuro) to record scalp EEG at home twice daily. From each serial EEG recording, brain network ictogenicity (BNI), a new biomarker of the propensity of the brain to develop seizures, will be extracted. A noninvasive wrist-worn device (Fitbit Charge 3; Fitbit Inc) will be used to collect non-EEG biosignals (heart rate, sleep quality index, and steps), and a smartphone app (Seer app; Seer Medical) will be used to collect data related to seizure occurrence, medication taken, sleep quality, stress, and mood. All data will be collected continuously for 6 months. Standardized questionnaires (the Post-Study System Usability Questionnaire and System Usability Scale) will be completed to assess the acceptability and feasibility of the procedure. BNI, continuous wrist-worn sensor biosignals, and electronic survey data will be correlated with seizure occurrence as reported in the diary to investigate their potential values as biomarkers of seizure risk. The EEG@HOME project received funding from Epilepsy Research UK in 2018 and was approved by the Bromley Research Ethics Committee in March 2020. The first participants were enrolled in October 2020, and we expect to publish the first results by the end of 2022. With the EEG@HOME study, we aim to take advantage of new advances in remote monitoring technology, including self-applied EEG, to investigate the feasibility of long-term disease self-monitoring. Further, we hope our study will bring new insights into noninvasively collected personalized risk factors of seizure occurrence and seizure propensity that may help to mitigate one of the most difficult aspects of refractory epilepsy: the unpredictability of seizure occurrence. PRR1-10.2196/25309.
Sections du résumé
BACKGROUND
BACKGROUND
Epileptic seizures are spontaneous events that severely affect the lives of patients due to their recurrence and unpredictability. The integration of new wearable and mobile technologies to collect electroencephalographic (EEG) and extracerebral signals in a portable system might be the solution to prospectively identify times of seizure occurrence or propensity. The performances of several seizure detection devices have been assessed by validated studies, and patient perspectives on wearables have been explored to better match their needs. Despite this, there is a major gap in the literature on long-term, real-life acceptability and performance of mobile technology essential to managing chronic disorders such as epilepsy.
OBJECTIVE
OBJECTIVE
EEG@HOME is an observational, nonrandomized, noninterventional study that aims to develop a new feasible procedure that allows people with epilepsy to independently, continuously, and safely acquire noninvasive variables at home. The data collected will be analyzed to develop a general model to predict periods of increased seizure risk.
METHODS
METHODS
A total of 12 adults with a diagnosis of pharmaco-resistant epilepsy and at least 20 seizures per year will be recruited at King's College Hospital, London. Participants will be asked to self-apply an easy and portable EEG recording system (ANT Neuro) to record scalp EEG at home twice daily. From each serial EEG recording, brain network ictogenicity (BNI), a new biomarker of the propensity of the brain to develop seizures, will be extracted. A noninvasive wrist-worn device (Fitbit Charge 3; Fitbit Inc) will be used to collect non-EEG biosignals (heart rate, sleep quality index, and steps), and a smartphone app (Seer app; Seer Medical) will be used to collect data related to seizure occurrence, medication taken, sleep quality, stress, and mood. All data will be collected continuously for 6 months. Standardized questionnaires (the Post-Study System Usability Questionnaire and System Usability Scale) will be completed to assess the acceptability and feasibility of the procedure. BNI, continuous wrist-worn sensor biosignals, and electronic survey data will be correlated with seizure occurrence as reported in the diary to investigate their potential values as biomarkers of seizure risk.
RESULTS
RESULTS
The EEG@HOME project received funding from Epilepsy Research UK in 2018 and was approved by the Bromley Research Ethics Committee in March 2020. The first participants were enrolled in October 2020, and we expect to publish the first results by the end of 2022.
CONCLUSIONS
CONCLUSIONS
With the EEG@HOME study, we aim to take advantage of new advances in remote monitoring technology, including self-applied EEG, to investigate the feasibility of long-term disease self-monitoring. Further, we hope our study will bring new insights into noninvasively collected personalized risk factors of seizure occurrence and seizure propensity that may help to mitigate one of the most difficult aspects of refractory epilepsy: the unpredictability of seizure occurrence.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
PRR1-10.2196/25309.
Identifiants
pubmed: 33739290
pii: v10i3e25309
doi: 10.2196/25309
pmc: PMC8088854
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e25309Informations de copyright
©Andrea Biondi, Petroula Laiou, Elisa Bruno, Pedro F Viana, Martijn Schreuder, William Hart, Ewan Nurse, Deb K Pal, Mark P Richardson. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 19.03.2021.
Références
Epilepsia. 2019 Nov;60(11):2204-2214
pubmed: 31608435
Ann Clin Transl Neurol. 2018 Dec 18;6(2):333-343
pubmed: 30847365
Epilepsy Behav. 2012 Jul;24(3):304-10
pubmed: 22652423
Epilepsy Res. 1995 Jun;21(2):125-32
pubmed: 7588587
J Psychosom Res. 2006 Jun;60(6):631-7
pubmed: 16731240
Neuroimage. 2010 Sep;52(3):1059-69
pubmed: 19819337
Epilepsia. 2020 Nov;61 Suppl 1:S11-S24
pubmed: 32385909
Epilepsia. 2013 Nov;54(11):1960-7
pubmed: 24111898
Ann Neurosci. 2016 Jul;23(2):100-11
pubmed: 27647960
J Neurol. 2018 Aug;265(8):1740-1752
pubmed: 29427026
Seizure. 2016 Oct;41:141-53
pubmed: 27567266
J Med Internet Res. 2019 Nov 28;21(11):e16273
pubmed: 31778122
Epilepsia. 2020 Nov;61 Suppl 1:S3-S10
pubmed: 32683686
JMIR Mhealth Uhealth. 2015 Nov 04;3(4):e101
pubmed: 26537656
Epilepsy Behav. 2018 Aug;85:141-149
pubmed: 29940377
Epilepsia. 2020 Apr;61(4):776-786
pubmed: 32219856
Epilepsia. 2012 May;53(5):e93-7
pubmed: 22432935
JMIR Mhealth Uhealth. 2018 Aug 09;6(8):e10527
pubmed: 30093371
Sci Rep. 2016 Jul 07;6:29215
pubmed: 27384316
Biomed Eng Online. 2019 Oct 30;18(1):106
pubmed: 31666082
Front Syst Neurosci. 2016 Jan 08;9:175
pubmed: 26778976
Neurology. 2003 Jan 14;60(1):10-6
pubmed: 12525711
Neurology. 2019 Nov 26;93(22):e2021-e2031
pubmed: 31645468
Neurology. 2007 Nov 13;69(20):1905-10
pubmed: 17998482
Epilepsia. 2007 Dec;48(12):2357-60
pubmed: 17651410
BMJ. 2012 Jul 17;345:e4576
pubmed: 22807075
Seizure. 1992 Mar;1(1):43-8
pubmed: 1344320
Neuroimage. 2010 Jul 15;51(4):1319-33
pubmed: 20304076
Ann Gen Psychiatry. 2007 Oct 30;6:28
pubmed: 17971199
Lancet Neurol. 2013 Jun;12(6):563-71
pubmed: 23642342
Int J Psychophysiol. 2014 Jan;91(1):30-5
pubmed: 24060755
Seizure. 2019 May;68:31-37
pubmed: 30391107
Ann Neurol. 2007 Oct;62(4):375-81
pubmed: 17253624
Epilepsia. 2013 Apr;54(4):e58-61
pubmed: 23398578
Epilepsy Behav. 2018 Aug;85:64-71
pubmed: 29908386
Seizure. 2018 Feb;55:48-56
pubmed: 29367145
J Med Internet Res. 2018 Jul 12;20(7):e10480
pubmed: 30001997
Epilepsy Behav. 2020 Jan;102:106717
pubmed: 31785481
Biomed Res Int. 2017;2017:5496196
pubmed: 29349078
Seizure. 2016 Jul;39:13-18
pubmed: 27205871
Epilepsia. 2013 Nov;54(11):1866-76
pubmed: 24117321
Front Neurol. 2014 Dec 08;5:261
pubmed: 25538679
PLoS One. 2014 Oct 10;9(10):e110136
pubmed: 25302690
Epilepsy Behav. 2018 Apr;81:62-69
pubmed: 29494935
Lancet Neurol. 2018 Nov;17(11):977-985
pubmed: 30219655
Eur J Neurol. 2005 Apr;12(4):245-53
pubmed: 15804240
Epilepsy Res. 2016 Nov;127:260-266
pubmed: 27665308
J Med Eng Technol. 2017 Oct;41(7):564-585
pubmed: 28994627
Clin Neurophysiol. 2019 Nov;130(11):2076-2087
pubmed: 31541985
J Cancer Educ. 2013 Mar;28(1):138-42
pubmed: 23275239
Epilepsy Behav. 2014 Apr;33:101-5
pubmed: 24632482
Lancet Neurol. 2018 Dec;17(12):1098-1108
pubmed: 30366868
Epilepsy Behav. 2014 Aug;37:291-307
pubmed: 25174001